Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
17 janv. 2024 08h00 HE
|
Enlivex Therapeutics Ltd
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel,...
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
20 déc. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis studyTopline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 ...
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
11 sept. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative,...
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
02 août 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as...
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
31 juil. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
26 juin 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50%...
Enlivex to Present at the 2023 Jefferies Healthcare Conference
06 juin 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
31 mai 2023 08h04 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
08 mai 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...